S
Spyre Therapeutics, Inc. (SYRE)
NMS – Real Time Price. Currency in USD
75.04
-1.39 (-1.82%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
75.04
-1.39 (-1.82%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.97 | 6.05 | 10 | |
| Quick ratio | 8.97 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 2M | 886K | N/A | N/A | N/A |
| Gross Profit | 365K | -78K | N/A | N/A | N/A |
| Operating Income | -85M | -118M | -209M | -220M | -242M |
| Net Income | -84M | -95M | -150M | -127M | -169M |
| EBITDA | -83M | -117M | -209M | -220M | -242M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -46.17 | 1.0 |
| Next quarter | N/A | -372.07 | 1.0 |
| Current year | N/A | -44.98 | 1.0 |
| Next year | N/A | -7.91 | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -33.12 | -5.7 | N/A | 3.3 |
| Y/Y | 999 | -91.21 | -23.32 | N/A | 3.3 |
| 3y average | 279.02 | -18.46 | 10.94 | -41.26 | 4.8 |
| 5y average | 349.7 | -12.82 | 13.61 | -24.5 | 5.0 |
| Weighted average score | 4.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Cash reserves $97.2M barely cover the upcoming debt maturities $0.0
Total current assets $764.0M exceed Total current liabilities $85.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$57.5M limits the company's ability to reinvest or pay down debt